Role of fibrates in the management of hypertriglyceridemia

American Journal of Cardiology

Volumn 83, Issue 9 B, 1999, Pages

  Rader, Daniel J ^a   Haffner, Steven M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CIPROFIBRATE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; MEVINOLIN; PRAVASTATIN;

CONFERENCE PAPER; DRUG EFFECT; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033551394     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00270-2     Document Type: Conference Paper

References (58)

1. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol a meta-analysis of population-based prospective studies . J Cardio Risk. 3:1996;213-219.
2. Santamarina-Fojo S., Brewer H.B. Jr. The familial hyperchylomicronemia syndrome. New insights into underlying genetic defects. JAMA. 265:1991;904-908.
3. Brunzell J.D., Schrott H.G., Motulsky A.G., Bierman E.L. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism. 25:1976;313-320.
4. Havel R.J. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol. 5:1994;102-109.
5. Davignon J., Cohn J.S. Triglyceride a risk factor for coronary heart disease . Atherosclerosis. 124:(suppl):1996;S57-S64.
6. Superko H.R. Beyond LDL cholesterol reduction. Circulation. 94:1996;2351-2354.
7. Grundy S.M. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 95:1997;1-4.
8. Brewer H.B. Jr, Zech L.A., Gregg R.E., Schwartz D., Schaefer E.J. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med. 98:1983;623-640.
9. Hegele R.A., Little J.A., Vezina C., Maguire G.F., Tu L., Wolever T.S., Jenkins D.J., Connelly P.W. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb. 13:1993;720-728.
10. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 52:1973;1544-1568.
11. Stampfer M.J., Krauss R.M., Ma J., Blanche P.J., Holl L.G., Sacks F.M., Hennekens C.H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:1996;882-888.
12. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischemic heart disease an eight-year follow-up in the Copenhagen Male Study . Circulation. 97:1998;1029-1036.
13. Fruchart J.C., Brewer H.B. Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol. 81:1998;912-917.
14. Miller D.B., Spence J.D. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 34:1998;155-162.
15. Kloer H.U. Structure and biochemical effects of fenofibrate. Am J Med. 83:1987;3-8.
16. Goa K.L., Barradell L.B., Plosker G.L. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs. 52:1996;725-753.
17. Turpin G., Bruckert E. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias. Atherosclerosis. 124:(suppl):1996;S83-S87.
18. Betteridge D.J. Ciprofibrate - a profile. Postgrad Med J. 69:(suppl 1):1993;S42-S49.
19. Schoonjans K., Staels B., Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 37:1996;907-925.
20. Wang C.S., McConathy W.J., Kloer H.U., Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 75:1985;384-390.
21. Wolfe B.M., Kane J.P., Havel R.J., Brewster H.P. Mechanism of the hypolipidemic effect of clofibrate on postabsorptive man. J Clin Invest. 52:1973;2146-2159.
22. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.C., Staels B., Auwerx J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 96:1995;741-750.
23. Zambón D., Ros E., Rodriguez-Villar C., Laguna J.C., Havel R.J. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol. 5:1994;102-109.
24. Tikkanen M.J., Laakso M., Ilmonen M., Helve E., Kaarsalo E., Kilkki E., Saltevo J. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes Care. 21:1998;477-481.
25. Farnier M., Bonnefous F., Debbas N., Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med. 154:1994;441-449.
26. Gholami K., Tavakoli N., Maleki M., Shafiee A. Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidemia. J Clin Pharm Ther. 23:1998;213-221.
27. Illingworth D.R., O'Malley J.P. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism. 39:1990;403-409.
28. Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A., Didangelos T.P., Carina M.V., Kranitsas D.F., Kontopoulos A.G. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 80:1997;608-613.
29. Glueck C.J., Oakes N., Speirs J., Tracy T., Lang J. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol. 70:1992;1-9.
30. Illingworth D.R., Bacon S. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia. Circulation. 79:1989;590-596.
31. Pasternak R.C., Brown L.E., Stone P.H., Silverman D.I., Gibson C.M., Sacks F.M. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Ann Intern Med. 125:1996;529-540.
32. Smit J.W., Jansen G.H., de Bruin T.W., Erkelens D.W. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am J Cardiol. 76:(suppl):1995;126A-128A.
33. Wicklund O., Angelin B., Bergman M., Berglund L., Bonjers G., Carlsson A., Linden T., Miettinen T., Odman B., Olofsson S.O., et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 94:1993;13-20.
34. Wirebaugh S.R., Shapiro M.L., McIntyre T.H., Whitney E.J. A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin. Pharmacotherapy. 12:1992;445-450.
35. Ellen R.L.B., McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 81:(suppl):1998;60B-65B.
36. Feher M.D., Foxton J., Banks D., Lant A.F., Wray R. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br Heart J. 74:1995;14-17.
37. Horsmans Y., Desager J.P., Harvengt C. Effects of combined bezafibrate-simvastatin appraised in healthy subjects. J Clin Pharmacol. 32:1992;422-426.
38. Hutchesson A.C., Moran A., Jones A.F. Dual bezafibrate-simvastatin therapy for combined hyperlipidemia. J Clin Pharm Ther. 19:1994;387-389.
39. Leitersdorf E., Muratti E.N., Eliav O., Meiner V., Eisenberg S., Dann E.J., Sehayek E., Peters T.K., Stein Y. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia comparative analysis with a fluvastatin-cholestyramine combination . Am J Med. 96:1994;401-407.
40. Leitersdorf E., Muratti E.N., Eliav O., Peters T.K. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Am J Cardiol. 76:(suppl):1995;84A-88A.
41. Lintott C.J., Scott R.S., Sharpe D.N., Nye E.R., Charleson H., French J.K., White H.D., Reuben S., Mailing T.J., Lewis G.R., et al. Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation. Med J Aust. 155:1991;433-436.
42. Yeshurun D., Abukarshin R., Elias N., Lanir A., Naschitz J.E. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination. Clin Ther. 15:1993;355-363.
43. Pierce L.R., Wysowski D.K., Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 264:1990;71-75.
44. A co-operative trial in the prevention of ischaemic heart disease using clofibrate. Br Heart J. 40:1978;1069-1118.
45. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet. 2:1980;379-385.
46. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet. 15:1984;600-604.
47. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., Mäenpää H., Mälkönen M., Mänttäri M., Norola S., Pasternack A., Pikkarainen J., Romo M., Sjöblom T., Nikkilä E.A. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317:1987;1237-1245.
48. de Faire U., Ericsson C.G., Hamsten A., Nilsson J. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Drugs Exp Clin Res. 21:1995;105-124.
49. Ericsson C.G. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. Eur Heart J. 19:(suppl H):1998;H37-H41.
50. Elkeles R.S., Diamond J.R., Poulter C., Dhanjil S., Nicolaides A.N., Mahmood S., Richmond W., Mather H., Sharp P., Feher M.D. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 21:1998;641-648.
51. Goldbourt U., Behar S., Reicher-Reiss H., Agmon J., Kaplinsky E., Graff E., Kishon Y., Caspi A., Weisbort J., Mandelzweig L. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 71:1993;909-915.
52. Goldbourt U., Brunner D., Behar S., Reicher-Reiss H. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J. 19:(suppl H):1998;H42-H47.
53. Verheugt F.W. Hotline sessions at the 20th European Congress of Cardiology. Eur Heart J. 20:1999;7-10.
54. Rubins H.B., Robins S.J., Iwane M.K., Boden W.E., Elam M.B., Fye C.L., Gordon D.J., Schaefer E.J., Schectman G., Wittes J.T. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 71:1993;45-52.
55. Papademetriou V., Narayan P., Rubins H., Collins D., Robins S. Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. HIT Investigators. Department of Veterans Affairs HDL Intervention Trial. Am Heart J. 136:1998;734-740.
56. Effect of simvastatin on coronary atheroma the Multicentre Anti-Atheroma Study (MAAS) . Lancet. 344:1994;633-638.
57. Jukema J.W., Bruschke A.V., van Boven A.J., Reiber J.H., Bal E.T., Zwinderman A.H., Jansen H., Boerma G.J., van Rappard F.M., Lie K.I., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 91:1995;2528-2540.
58. , Steiner G. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. Diabetologica. 39:1996;1655-1661.